Press Release

Awamedica Marks Its Fourth Consecutive Participation in Medical Kurdistan — Diamond Sponsor in 2026

February 11, 2026•Rotana Hotel, Erbil

Awamedica is proud to announce its participation in the 4th Medical Kurdistan International Conference & Exhibition, held on 11–13 February 2026 at the Rotana Hotel in Erbil.

For the fourth consecutive year, Awamedica joined this distinguished scientific gathering — and in 2026, the company was honored to serve as Diamond Sponsor.

Organized in collaboration with the University of Kurdistan Hewlêr, this year’s conference was held under the theme “Quality Medical Education at the Service of the Local Population,” bringing together physicians, pharmacists, healthcare professionals, academics, policymakers, and representatives from the pharmaceutical and commercial sectors.

Awamedica’s continued participation reflects its sustained commitment to:

Supporting high-quality medical education
Strengthening collaboration between industry and healthcare professionals
Promoting responsible pharmaceutical practices
Contributing to the advancement of healthcare standards in Kurdistan and the wider region

Throughout the conference, Awamedica engaged with healthcare professionals and stakeholders, reinforcing its position as a trusted local pharmaceutical manufacturer committed to quality, safety, and innovation.

As a company rooted in the community, Awamedica believes that advancing healthcare requires partnership, dialogue, and shared responsibility. Participation in Medical Kurdistan aligns with the company’s broader mission to preserve and improve patient health through high-quality pharmaceutical products and ethical practices.

Awamedica looks forward to continuing its support of scientific initiatives that elevate medical education and strengthen healthcare systems across the region.

Blog

Phase IV Post-Marketing Surveillance: Monitoring Safety After Regulatory Approval

Phase IV studies, also known as post-marketing surveillance, evaluate the long-term safety and effectiveness of medicines after regulatory approval. These studies contribute to ongoing benefit–risk assessment in real-world clinical settings.

Drug Recalls: Regulatory Process and Manufacturer Responsibilities

Drug recalls are structured regulatory actions taken to address quality, safety, or labeling concerns associated with medicinal products. Clear procedures and defined responsibilities ensure patient protection and supply chain integrity.

Safe Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Gastrointestinal and Cardiovascular Considerations

Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation management. Appropriate patient selection and risk assessment are essential to minimize gastrointestinal and cardiovascular complications.

How FDA and EMA Issue Safety Alerts: Regulatory Communication in Pharmacovigilance

Regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) issue safety alerts to communicate emerging risks associated with medicinal products. These alerts support timely risk mitigation and informed clinical decision-making.

1 of 3